Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the quarter and six months ended June 30, 2025. Total revenues for the six months ended June 30, 2025, were $6.704 billion, a slight increase from $6.692 billion in the same period of 2024. Net income for the first six months of 2025 was $2.200 billion, or $20.02 per diluted share, compared to $2.154 billion, or $18.68 per diluted share, in the prior year's period. The company's balance sheet shows total assets of $38.219 billion as of June 30, 2025, and total stockholders' equity of $29.939 billion. The company saw a decrease in net product sales, primarily driven by a significant decline in EYLEA sales, which was partially offset by growth in EYLEA HD and Dupixent. Collaboration revenues, largely from the Sanofi and Bayer partnerships, showed a substantial increase, driven by higher profit shares, particularly from Dupixent. Operating expenses, notably research and development, increased year-over-year, reflecting continued investment in the company's pipeline. Investors should note the ongoing legal proceedings related to EYLEA biosimilar challenges and the company's active share repurchase program, which repurchased approximately $2.122 billion of common stock during the first six months of 2025. The company also declared and paid quarterly dividends.
Financial Highlights
47 data points| Revenue | $3.68B |
| R&D Expenses | $1.42B |
| SG&A Expenses | $634.20M |
| Operating Expenses | $2.60B |
| Operating Income | $1.08B |
| Net Income | $1.39B |
| EPS (Basic) | $13.24 |
| EPS (Diluted) | $12.81 |
| Shares Outstanding (Basic) | 105.10M |
| Shares Outstanding (Diluted) | 108.60M |
Key Highlights
- 1Total revenues for the six months ended June 30, 2025, increased slightly to $6.704 billion from $6.692 billion in the same period of 2024.
- 2Net income for the six months ended June 30, 2025, rose to $2.200 billion ($20.02 per diluted share) from $2.154 billion ($18.68 per diluted share) in the prior year.
- 3Net product sales decreased by $633.3 million for the six months ended June 30, 2025, primarily due to a decline in EYLEA sales, partially offset by growth in EYLEA HD and Dupixent.
- 4Collaboration revenue increased significantly, driven by higher profit shares from the Sanofi collaboration, notably from Dupixent sales.
- 5Research and development expenses increased by $300.7 million for the six months ended June 30, 2025, reflecting continued investment in pipeline development.
- 6The company repurchased approximately $2.122 billion of its common stock during the first six months of 2025.
- 7Regeneron continues to be involved in significant patent litigation concerning EYLEA and its biosimilars.